0001516551-24-000059.txt : 20240610 0001516551-24-000059.hdr.sgml : 20240610 20240610092739 ACCESSION NUMBER: 0001516551-24-000059 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240610 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240610 DATE AS OF CHANGE: 20240610 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Skye Bioscience, Inc. CENTRAL INDEX KEY: 0001516551 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 450692882 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-42009 FILM NUMBER: 241031612 BUSINESS ADDRESS: STREET 1: 11250 EL CAMINO REAL, SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 410-0266 MAIL ADDRESS: STREET 1: 11250 EL CAMINO REAL, SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Emerald Bioscience, Inc. DATE OF NAME CHANGE: 20190325 FORMER COMPANY: FORMER CONFORMED NAME: Nemus Bioscience, Inc. DATE OF NAME CHANGE: 20141030 FORMER COMPANY: FORMER CONFORMED NAME: LOAD GUARD LOGISTICS, INC. DATE OF NAME CHANGE: 20121107 8-K 1 skye-20240610.htm 8-K skye-20240610
FALSE000151655100015165512024-06-102024-06-10

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): June 10, 2024
 
SKYE BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)

Nevada 000-55136 45-0692882
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification Number)
 
11250 El Camino Real, Suite 100, San Diego, CA 92130
(Address of principal executive offices)
 
(858) 410-0266
(Registrant’s telephone number, including area code)
_________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, par value $0.001
SKYE
Nasdaq Global Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 8.01 Other Events.

On June 10, 2024, Skye Bioscience, Inc. (the “Company,” “we” and “our”) issued a press release announcing that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion (“OE”) in patients with primary open-angle glaucoma or ocular hypertension did not meet its primary endpoint for lowering intraocular pressure. The Company intends to discontinue the clinical development of SBI-100 OE and all research and development associated with SBI-100 including its ophthalmology pipeline to direct its clinical development resources to its obesity program. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The press release will also be available under the “Investors” section of the Company’s website.

FORWARD LOOKING STATEMENTS

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our product development, business strategy, the timing of clinical trials and published findings, and expected operating runway. Such statements and other statements in this Current Report on Form 8-K that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1
104Cover Page Interactive Data File (embedded within the inline XBRL document)



SIGNATURES
 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
                        SKYE BIOSCIENCE, INC.
  
  
Dated: June 10, 2024
/s/  Punit Dhillon
 Name: Punit Dhillon
 Title: Chief Executive Officer

 EX-99.1 2 a240610_skyexnrxsbip2atopl.htm EX-99.1 Document

Skye Concentrates Strategy and Clinical Development Focus on
Nimacimab Metabolic Program

SBI-100 Ophthalmic Emulsion Phase 2a trial does not achieve target product profile; program discontinued

Phase 2 study of Nimacimab in obesity expected to start in Q3 2024

Cash runway extended into 2027

SAN DIEGO, June 10, 2024 – Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, announced that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma ("POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure (“IOP”). Skye intends to discontinue clinical development and spending related to SBI-100 OE and any R&D associated with SBI-100, including its ophthalmology pipeline, and direct all clinical development resources to its metabolic program, extending its operating runway into 2027. Skye’s Phase 2 obesity clinical trial for its differentiated CB1 inhibitor, Nimacimab, is expected to begin dosing in Q3 2024.

In this Phase 2a double-masked, randomized, placebo-controlled trial of SBI-100 OE, 56 patients with elevated IOP diagnosed with POAG or OHT received dosing of 1.0% or 0.5% concentrations of SBI-100 OE, or placebo, consisting of one drop in each eye, twice a day, for 14 days. The primary endpoint was to assess change in diurnal intraocular pressure in the treated arms vs. placebo. The study did not achieve a statistically significant improvement in IOP over placebo. The drug was safe and all treated patients completed the study with no early discontinuations due to adverse events.

“The results of this Phase 2a clinical trial of SBI-100 OE unfortunately did not meet our pre-set criteria for continuation and further development of this molecule as an alternative treatment for glaucoma and ocular hypertension. We will continue to evaluate the full data set and intend to publish findings,” said Tu Diep, Skye’s Chief Development Officer. “We thank the patients and investigators who supported our clinical investigation of SBI-100 OE in this study.”

“In the last year we laid the groundwork for our metabolic program with the goals of diversifying our product portfolio’s disease targets and therapeutic mechanisms, while significantly expanding our clinical and business opportunities. With this data outcome from our glaucoma program, we will now focus 100% of our efforts on broadening our metabolic clinical pipeline,” said Punit Dhillon, Skye’s CEO and Chair. “We believe that Nimacimab’s unique mechanism of peripheral CB1 inhibition positions it to potentially contribute to the need for higher-quality, sustainable weight loss and better treatments for co-morbid conditions amidst an incretin-biased anti-obesity therapeutic landscape. We will look forward to sharing updates on this clinical program and advancing Nimacimab through to data in 2025.”

About Nimacimab

Nimacimab is a first-in-class humanized monoclonal antibody that acts as a negative allosteric modulator to inhibit CB1 signaling in the periphery. Inhibition of CB1 has shown anti-fibrotic, anti-inflammatory, and metabolic mechanisms of action with potential to address a broad range of diseases with notable


unmet medical needs such as obesity, chronic kidney disease, and metabolic dysfunction-associated steatohepatitis (MASH).

About Skye Bioscience

Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases with metabolic, inflammatory, and fibrotic processes. Backed by specialist life science investors, Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with significant clinical and commercial differentiation. Skye plans to start a Phase 2 clinical trial in obesity in Q3 2024 for Nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of Nimacimab and a GLP-1R agonist. Clinical development of SBI-100 Ophthalmic Emulsion for glaucoma and ocular hypertension will be discontinued. Please visit: https://www.skyebioscience.com.

CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266

LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306

Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our product development, business strategy, the timing of clinical trials and published findings, and expected operating runway. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K


and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.

 EX-101.SCH 3 skye-20240610.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 skye-20240610_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 skye-20240610_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line Two Entity Address, Address Line Two Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications Document Information [Line Items] Document Information [Line Items] City Area Code City Area Code Cover [Abstract] Document Type Document Type Document Information [Table] Document Information [Table] Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 6 skye-20240610_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover Page
Jun. 10, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 10, 2024
Entity Registrant Name SKYE BIOSCIENCE, INC.
Entity Incorporation, State or Country Code NV
Entity File Number 000-55136
Entity Tax Identification Number 45-0692882
Entity Address, Address Line One 11250 El Camino Real
Entity Address, Address Line Two Suite 100
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code 858
Local Phone Number 410-0266
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001516551
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( '-+RE@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !S2\I8YS*@!N\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)OIW^D0NCFLN))07!!\18FL[O!I@W)2+MO;UIWNX@^@,?,_/+- M-S M>HE#H.

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 20 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://skyebioscience.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports skye-20240610.htm skye-20240610.xsd skye-20240610_def.xml skye-20240610_lab.xml skye-20240610_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "skye-20240610.htm": { "nsprefix": "skye", "nsuri": "http://skyebioscience.com/20240610", "dts": { "inline": { "local": [ "skye-20240610.htm" ] }, "schema": { "local": [ "skye-20240610.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "definitionLink": { "local": [ "skye-20240610_def.xml" ] }, "labelLink": { "local": [ "skye-20240610_lab.xml" ] }, "presentationLink": { "local": [ "skye-20240610_pre.xml" ] } }, "keyStandard": 20, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 20 }, "report": { "R1": { "role": "http://skyebioscience.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240610.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240610.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentInformationLineItems", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentInformationTable", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine2", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r0" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r0" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r0" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r0" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r4" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001516551-24-000059-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001516551-24-000059-xbrl.zip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end XML 18 skye-20240610_htm.xml IDEA: XBRL DOCUMENT 0001516551 2024-06-10 2024-06-10 false 0001516551 8-K 2024-06-10 SKYE BIOSCIENCE, INC. NV 000-55136 45-0692882 11250 El Camino Real Suite 100 San Diego CA 92130 858 410-0266 false false false false false